Influenza
Conditions
Interventions
Experimental group:Take dexibuprofen
Sponsors
The Seventh Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
1 Years to 12 Years
Inclusion criteria
Inclusion criteria: (1) Children who have been signed by a parent or legal guardian on an informed consent form; (2) Age>=1 year and =38.2°C, <41°C, or discomfort and depressed mood due to fever; (4) White blood cell count (WBC) <=15×10^9/L or absolute neutrophil count <=10×10^9/L; (5) C-reactive protein (CRP) or hypersensitive C-reactive protein (hs-CRP) <=2 times the upper limit of the reference value.
Exclusion criteria
Exclusion criteria: 1 Those who have taken ibuprofen oral suspension or used preparations containing ibuprofen within 6 hours at the time of presentation; 2. Those who have taken acetaminophen suspension or preparations containing acetaminophen within 6 hours of presentation; 3. Those who have used proprietary Chinese medicines with antipyretic ingredients within 6 hours at the time of consultation; 4. Those who have clear foci or indications of bacterial infection, or/and suspected respiratory diseases caused by lower respiratory tract infection requiring hospitalization; 5 Children with severe malnutrition; 6. Patients with heart failure or other organ insufficiency at the time of consultation; 7. Those who have signs of dehydration or high fever crisis at the time of presentation; 8 Those who are at risk of high fever within 6 months prior to the visit; 9 Patients with active peptic ulcer at the time of presentation; 10. Those who have a potential bleeding tendency or active bleeding manifestations at the time of presentation; 11 Those who have been allergic to ibuprofen or acetaminophen drugs in the past; History of wheezing caused by aspirin and other nonsteroidal anti-inflammatory drugs Patients with wheezing, rhinitis or urticaria; 12 Those who have a history of kidney, liver, lung, endocrine, hematologic, and heart diseases before the visit, and have been treated less than 6 months after the end of treatment; 13 Those with central nervous system abnormalities at the time of consultation; 14 Patients with currently uncontrolled type 1 or type 2 diabetes mellitus; 15. Consider patients with fever caused by infection with other highly infectious pathogens (e.g., tuberculosis, novel coronavirus, etc.); 16. Those who are judged by the investigator to be unsuitable for participating in this study due to other uncertain factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body temperature change within 1 hour of first dose; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of people with normal body temperature (=37.2?) within 2 hours of the first dose;The amount of body temperature change and the average time to normalize body temperature (=37.2?) within 4 hours of the first dose;Circulatory system conditions within 4 hours of first dose;Improvement in child comfort 4 hours after the first dose;Evaluation of gastrointestinal symptoms within 24 hours and 72 hours of first dose; | — |
Countries
China
Contacts
Public ContactChun Chen
The Seventh Affiliated Hospital Sun Yat-sen University
Outcome results
None listed